Risk factors for Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) acquisition among contacts of newly diagnosed CP-CRE patients

Infection Control and Hospital Epidemiology

Volumn 37, Issue 10, 2016, Pages 1219-1225

  Schwartz Neiderman, Anat ^a   Braun, Tali ^a   Fallach, Noga ^a   Schwartz, David ^a   Carmeli, Yehuda ^a,b   Schechner, Vered ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b MINISTRY OF HEALTH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE KPC; CEPHALOSPORIN DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CARBAPENEMASE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CASE CONTROL STUDY; CONTROLLED STUDY; ENTEROBACTERIACEAE INFECTION; HOSPITALIZATION; HUMAN; INFECTION RISK; ISRAEL; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; RISK FACTOR; TERTIARY CARE CENTER; AGED; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CROSS INFECTION; FECES; FEMALE; HETEROZYGOTE; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; STATISTICAL MODEL; TRANSMISSION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARRIER STATE; CASE-CONTROL STUDIES; CEPHALOSPORINS; CROSS INFECTION; ENTEROBACTERIACEAE INFECTIONS; FECES; FEMALE; HUMANS; ISRAEL; LOGISTIC MODELS; MALE; MIDDLE AGED; RESPIRATION, ARTIFICIAL; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84988837588     PISSN: 0899823X     EISSN: 15596834     Source Type: Journal    
DOI: 10.1017/ice.2016.153     Document Type: Article

References (30)

1. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarlia GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014;58:654-663.
2. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015;70:2133-2143.
3. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:1028-1033.
4. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009;30:1180-1185.
5. Fraenkel-Wandel Y, Raveh-Brawer D, Wiener-Well Y, Yinnon AM., Assous MV. Mortality due to blaKPC Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother 2016;71:1083-1087.
6. Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 2015;59:5873-5884.
7. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52:848-855.
8. Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clin Infect Dis 2014;58:697-703.
9. Wiener-Well Y, Rudensky B, Yinnon AM, et al. Carriage rate of carbapenem-resistant Klebsiella pneumoniae in hospitalised patients during a national outbreak. J Hosp Infect 2010;74:344-349.
10. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-1106.
11. Kitchel B, Rasheed JK, Patel JB, et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009;53:3365-3370.
12. Goren MG, Carmeli Y, Schwaber MJ, Chmelnitsky I, Schechner V, Navon-Venezia S. Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patients. Emerg Infect Dis 2010;16:1014-1017.
13. Adler A, Khabra E, Paikin S, Carmeli Y. Dissemination of the blaKPC gene by clonal spread and horizontal gene transfer: comparative study of incidence and molecular mechanisms. 2016. [Epub ahead of print].
14. Sidjabat HE, Silveira FP, Potoski BA, et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis 2009;49:1736-1738.
15. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update-CRE Toolkit. Centers for Disease Control and Prevention website. http://www.cdc.gov/hai/pdfs/cre/CRE-guidance-508.pdf. Accessed on January 8, 2016.
16. Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010;31:620-626.
17. Calfee D, Jenkins SG. Use of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patients. Infect Control Hosp Epidemiol 2008;29:966-968.
18. Lerner A, Adler A, Abu-Hanna J, Cohen Percia S, Kazma MatalonM, Carmeli Y. Spread of KPC-producing carbapenem-resistant Enterobacteriaceae: the importance of super-spreaders and rectal KPC concentration. Clin Microbiol Infect 2015;21(470):e471-e477.
19. Schechner V, Straus-Robinson K, Schwartz D, et al. Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. J Clin Microbiol 2009;47:3261-3265.
20. EllingtonMJ, Kistler J, LivermoreDM, WoodfordN.Multiplex PCR for rapid detection of genes encoding acquired metallobetallactamases J Antimicrob Chemother 2007 59 321-322.
21. Navon-Venezia S, Leavitt A, Schwaber MJ, et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009;53:818-820.
22. Katz S, Ford AB, Moskowitz RW, Jackson BA, JaffeMW. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
23. Swaminathan M, Sharma S, Poliansky Blash S, et al. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity. Infect Control Hosp Epidemiol 2013;34:809-817.
24. Chitnis AS, Caruthers PS, Rao AK, et al. Outbreak of carbapenem-resistant enterobacteriaceae at a long-Term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol 2012;33:984-992.
25. Tosh PK, McDonald LC. Infection control in the multidrugresistant era: tending the human microbiome. Clin Infect Dis 2012;54:707-713.
26. Ahn JY, Song JE, Kim MH, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study. Am J Infect Control 2014;42:621-625.
27. Ling ML, Tee YM, Tan SG, et al. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control 2015;4:26.
28. Kwak YG, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11:165-169.
29. Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ. Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev 2013;26:289-307.
30. Papadimitriou-OlivgerisM, MarangosM, Fligou F, et al.Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission J Antimicrob Chemother 2012 67 2976-2981.